Frontiers in Oncology · 2019 · 47 citations · 21 references
MedicineOncologyPharmacotherapyMetastasisMolecular OncologyOcular OncologyConjunctival DiseaseConjunctival TumorsMelanoma PharmacotherapyOcular Surface NeoplasiaOcular TumorsTargeted Cancer TherapyBraf V600 MutationsBraf V600e MutationCutaneous Metastatic TumorsMalignant Conjunctival TumorsMek InhibitionMek InhibitorsMetastatic Conjunctival MelanomaMetastatic Melanoma Treatment
Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.
21
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty, J. Infante, Adil Daud et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text
Medicine, Oncology, Pharmacology +16
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text
Medicine, Oncology, Pharmacotherapy +14
Incidence of noncutaneous melanomas in the U.S.
Colleen C. McLaughlin, Xiao‐Cheng Wu, Ahmedin Jemal et al. · Cancer · 2005 · 732 citations
Medicine, Dermatology, Oncology +12